Peroxisome proliferator-activated receptors gamma (PPARγ) are ligand-activated controllers of various metabolic actions and insulin sensitivity. PPARγ is thus considered as an important target to treat type 2 diabetes. Available PPARγ drugs (full agonists) have robust insulinsensitizing properties but are accompanied by severe side effects leading to complicated health problems. Here, we have used molecular docking and a molecular dynamics simulation study to find a novel PPARγ ligand from a natural product. Our study suggests that the inhibition of ceramicine B in the PPARγ ligand-binding domain (LBD) could act as a partial agonist and block cdk5-mediated phosphorylation. This result may provide an opportunity for the development of new anti-diabetic drugs by targeting PPARγ while avoiding the side effects associated with full agonists.
INTRODUCTION
Peroxisome proliferator-activated receptor gamma (PPARγ), a nuclear receptor, is highly expressed in adipose tissue and controls hundreds of genes to regulate diverse biological functions, which includes glucose metabolism, lipid metabolism, and insulin sensitivity [1] .
PPARγ dynamically shuttles between the nucleus and cytoplasm, but after binding with the agonists, it forms a heterodimer with the retinoid X receptor (RXR) and co-activators. This heterodimer is then translocated to the nucleus, where it regulates target genes involved in different metabolic functions and improves insulin sensitivity. Consequently, PPARγ has been considered as a suitable drug target for the treatment of type 2 diabetes.
Thiazolidinediones (TZDs), such as pioglitazone and rosiglitazone, which are full agonists of PPARγ, are highly effective for this purpose, and they effectively lower blood glucose levels [2] [3] [4] [5] . Full agonists bind in pocket I of the LBD of PPARγ and form hydrogen bonds with the Ser289, His323, His449 and Tyr473 residues, leading to a conformational change of H12 in the LBD [6] . This remodeling of the LBD allows PPARγ to dock with transcriptional coactivators and results in its activation [7] . Unfortunately, the use of TZDs is also associated with undesirable side effects, such as fat accumulation, fluid retention, cancer, loss of bone density and an increased risk of heart failure [8] [9] [10] [11] . As a consequence, TZDs are no longer recommended for the treatment of type 2 diabetes. This ensures the need for new selective PPARγ ligands with improved clinical profiles.
Recent studies suggest that the obesity-induced CDK5-mediated phosphorylation of PPARγ at Ser245 (Ser273 for PPARγ2) results in the dysregulated expression of a series of genes associated with insulin resistance, which ultimately leads to diabetes [12, 13] . In the same study, it was also demonstrated that PPARγ ligands are capable of blocking this phosphorylation and are able to normalize the dysregulation of the PPARγ-target gene. These compounds (partial agonists) have a unique binding mode in the ligand-binding pocket of PPARγ. Current findings show that partial agonists bind in the region between H3, the Ω-loop and the β-sheet, which form branch II of the PPARγ LBD, and that the region is different from the binding domain of a PPARγ full agonist. Most of the partial agonists interact via hydrogen bonding with Ser342 and via several hydrophobic interactions with the residues of branch II of the LBD of PPARγ, which causes the stabilization of the β-sheet/Ser245 surface and blocks phosphorylation. This mechanism exhibits antidiabetic effects similar to those of full agonists through the inhibition of PPARγ while ameliorating the side effects caused by the PPARγ transcriptional activity [12, 14, 15] . Until now, a number of PPAR partial agonists have been reported, but none of them are currently FDA approved [16] [17] [18] [19] [20] [21] . A few of these partial agonists have progressed through Phase II clinical trials, and several have not yet been tested for the later phases. Additionally, it has been reported that partial agonists exhibit a certain amount of transcriptional activation [21] . Thus, investigation on a new kind of partial agonist merits an intensive research focus.
Here, we have examined the agonist activity of ceramicines A-L (Figure 1 ) on PPAR using molecular docking and a molecular dynamics simulation study. Ceramicine is similar in size to most of the other PPAR partial agonists [19, 22] , as it consists of a phenanthrene ring with a large variation of moieties at different positions, and both cyclopentane and furan ring systems ( Figure 1) . A recent experimental study suggests that ceramicine B acts as an antilipid droplets accumulation agent by interrupting the phosphorylation of FoxO1, which leads to the down regulation of the transactivation activity of PPARγ [22] ; furthermore, studies on partial agonists reveal that the PPARγ activation by an H12-independent mechanism subsequently decreases the transcriptional activity of PPARγ [14, 15] . 
RESULTS AND DISCUSSION

Molecular docking analysis
In this study, we have examined the binding affinities of ceramicines A-L, Chelerythrine and SR1664 ( Figure 1 ) using the AutoDock4 molecular docking program. Molecular docking is a computational method that performs the virtual screening of drug-like compounds based on target structures and identifies appropriate confirmations with a binding affinity score. This gives the fastest and most accurate prediction of drug-like candidates for a target protein and allows for further biological testing. Twelve ceramicine compounds (A to L) are known to originate from the bark of Malaysian C. ceramicus [23] [24] [25] [26] Figure 2C illustrates the lowest energy docking poses of ceramicines L, F and G, which shows that the moiety in the phenanthrene ring interacts with the HIS323, TYR327, SER89, CYS285, ARG288 residues of branch I, maintaining hydrogen bonds with the CYS285 and GLY284 residues. The furan ring of these ceramicines reaches the β-sheet region of the LBD and We next evaluated the ADMET properties of ceramicine B, C and G by means of the Lipinski rule [27] using the FAFDrugs3 server [28] . The different parameters predicted were molecular weight, number of hydrogen bond donors and acceptors, topological PSA, number of rotatable bonds and log P. The ADMET parameters of the compounds are shown in Supplementary Table S1, which reveals that the values of the descriptors are within the optimum range followed by drug molecules. All three ceramicine compounds satisfied the Lipinski rule of five and were thus considered for the subsequent molecular dynamics simulation studies, which were performed to obtain the orientations of the compounds at the active site under dynamic conditions.
Molecular dynamics simulation analysis
A molecular dynamic study has been performed for the lowest energy conformations of ceramicines B, C and G. The best docking poses of these ceramicines in the docking simulation illustrate that they interact with the residues of branch II of the ligand binding pocket of the PPARγ target protein(PDB ID: 2F4B), which is similar to other partial agonists reported in previous studies [16] [17] [18] ; however, the docking simulation only provides a static interaction mode of the protein-ligand complex. To investigate the protein-ligand interaction stability under dynamic conditions, a 100ns molecular dynamics simulation for the proteinligand complexes has thus been performed and compared with the dynamic behavior of the uncomplexed PPARγ protein. To investigate the dynamics of the important residues in the complexes compared to the uncomplexed form, the root mean square fluctuations (RMSF) of the rC α atoms of the protein were calculated, as shown in Figure 4 .The figure represents reduced RMSF values for H3 and the β-sheet when complexed with ceramicine B relative to other considered complexes. The displacement of the H12 residue of the PPARγ-ceramicine B complex is comparable to that of the uncomplexed form, whereas in the inhibition of ceramicine C, ceramicine G highly stabilizes helix 12; thus, RMSF variation shows that ceramicine B stabilizes the H3, β-sheet and Ser245 regions more strongly than the other ceramicines, which could indicate more efficiency in blocking the Cdk5-mediated phosphorylation of Ser245 [29] . Conversely, the dynamics of H12 remain unaffected due to the inhibition of ceramicine B, which reflects the transcriptional activity-independent inhibition of PPARγ [14, 15] .Hence, ceramicine B could act as the most significant PPARγ partial agonist in comparison to other ceramicines. To understand the interaction of ceramicines with PPARγ during the course of the simulation, the number of hydrogen bonds formed with different residues of the LBD has been calculated ( Figure 6 ), and the pdb file at 100ns has been taken out to check the final confirmation of the inhibitor in the binding pocket. Figure 5 depicts the final binding modes of ceramicines B, C and G, which shows that all the ceramicines moved from their static docking poses during simulation due to the lack of constant hydrogen bond interactions with particular residues (Figure 6) . Ceramicines C and G maintain their conformations, similar to other reported partial agonists [16, 17] , and hydrogen bonding with Ser342 is significantly lower.
Ceramicine C forms the maximum number of hydrogen bond contacts with Arg288, and ceramicine G forms the maximum number with Gly284. Ceramicine B, however, exhibits a different binding conformation previously not reported for any other partial agonist. After few nanoseconds of the simulation, ceramicine B moved to the position in (shown in Figure   5 ) which it forms hydrogen bonds with Ser342 and Gln345, and its furan ring forms a π-π stacking interaction with Phe247.Additionally, ceramicine B maintains a greater number of hydrogen bond contacts with Ser342 during the simulation in comparison to the other ceramicines. Thus, the new binding conformation of ceramicine B could be an effective PPARγ partial agonist, as it highly stabilizes the β-sheet/Ser245 region but does not affect the dynamics of H12. 
CONCLUSIONS
MATERIAL AND METHODS
Data set
The crystal structures of the PPARγ (isoform 1) receptor protein of Protein Data Bank (PDB) ID 2F4B [30] were downloaded from RCBS Protein Data Bank (http://www.pdb.org). The bound ligand and unwanted atoms were removed from the protein structure and minimized using the GROMACS-4.5.6 software package [31] . The 3D structures of ceramicines A-L were generated by using CORINA software, (https://www.molecular-networks.com/), which takes Isomeric SMILES from the Pubchem compound database (http://www.ncbi.nlm.nih.gov/pccompound), and the structure was optimized with the help of Chimera 1.6.2.
Molecular docking and virtual screening
The docking study of the considered molecules into the PPARγ active site was performed with AutoDock4 [32] . AutoDock is one of the most widely used docking software programs that uses a Lamarckian genetic algorithm to predict the docking conformation between protein and ligand [33] . AutoDock Tools 1.5.6 was employed to prepare the protein and ligand and to perform the docking simulation. During the docking process, the protein was kept rigid and the ligands were flexible with all their torsional bonds free to rotate. A cubic grid box of size 60 Å×60Å×60 Å with points separated by 0.375 Å was generated and encompassed all the active site residues of PPARγ. All the default parameters were applied except the number of GA runs, which was set to 100.At the end of each docking, the lowest energy conformation was considered as the best binding conformation between each considered molecule and PPARγ. Cluster analysis showed that more than 20 percent of docking poses had the lowest energy conformations in each docking study.
The FAF Drugs3 web server [28] was used to analyze the ADMET properties of the bestdocked ceramicine compounds obtained from the AutoDock result. ADMET properties play an extremely crucial role in the discovery and development of novel drugs at the earlier stage, as unfavorable ADMET properties have been identified as a major cause of failure even for the most promising drug candidate molecules [34] . While calculating these properties using the FAFDrugs3 server, all the filtering options were kept as default except the -logP computation program‖ and -physchem filters‖, which were set as -XLOGP3‖ and -Lipinski-RO5‖, respectively. According to this, the ligands were screened by Lipinski's rule of five, which suggests that compounds are within the acceptable range for a drug molecule if they possess a logP of less than 5, a molecular weight of less than 500, fewer than ten rotatable bonds and no more than 5 hydrogen-bond donors and ten hydrogen-bond acceptors.
Molecular dynamic simulation
The molecular dynamics simulations of the PPARγ protein and previously screened PPARγ-ceramicine complexes were performed using GROMACS-4.5.6 software [35] under the GROMOS96 53a6 force field [36, 37] .The topology files of ceramicine compounds were generated using the online Automated Topology Builder (ATB) server, which applies quantum mechanical calculations combined with a knowledge-based approach to derive the GROMACS compatible force field parameters [38] . All the complexes were handled separately by putting them into a cubic box and were solvated by using the SPC216 water model. Na ions were added to each system to electrically neutralize the total charge by using the genion tool of the GROMACS package, which randomly substitutes water molecules with ions at the most favorable electrostatic potential positions. This was followed by energy minimization using a steepest decent algorithm with a maximum step size of 0.01 nm, maintaining a tolerance of 1000 kJ/mol/nm. The system was then subjected to equilibration at 300 K and 1 bar for 100ps under the conditions of position restraints for heavy atoms and LINCS constraints for all bonds [35] . Finally, the full system was subjected to a 100 ns MD simulation run, and the corresponding atom coordinates were stored every 0.002 ps during the simulation for later analyses.
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